Sugi Predict

Sugi Predict / Compounds / SCHEMBL922071

SCHEMBL922071

SCHEMBL922071

NC1=NN=C(N)C1=NNc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DEPTOR Q8TB45 2/20 0.53
▸ ALDH1A1 P00352 8/20 0.44
▸ HTT P42858 2/20 0.44
▸ NOX1 Q9Y5S8 1/20 0.41
▸ MEN1 O00255 8/20 0.39
▸ KMT2A Q03164 8/20 0.39
▸ GAA P10253 7/20 0.39
▸ RAB9A P51151 4/20 0.39
▸ NPC1 O15118 2/20 0.39
▸ GFER P55789 2/20 0.39
▸ MAPT P10636 9/20 0.39
▸ TDP1 Q9NUW8 4/20 0.39
▸ CYP1A1 P04798 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CYP1B1 Q16678 1/20 0.38
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ L3MBTL1 Q9Y468 3/20 0.37
▸ POLB P06746 2/20 0.37
▸ HSP90AA1 P07900 1/20 0.37
▸ VCP P55072 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL922102 0.93 ALDH1A1 (0.48) DEPTORALDH1A1HTTNOX1MEN1
SCHEMBL924489 0.89 DEPTOR (0.43) DEPTORALDH1A1HTTNOX1MEN1
SCHEMBL923301 0.87 DEPTOR (0.46) DEPTORALDH1A1HTTNOX1MEN1
SCHEMBL923300 0.87 DEPTOR (0.46) DEPTORALDH1A1HTTNOX1MEN1
SCHEMBL922393 0.86 DEPTOR (0.44) DEPTORALDH1A1HTTNOX1MEN1
SCHEMBL922391 0.86 DEPTOR (0.44) DEPTORALDH1A1HTTNOX1MEN1
SCHEMBL921686 0.84 MGLL (0.41) DEPTORALDH1A1HTTMEN1KMT2A
SCHEMBL922003 0.84 SCN5A (0.46) DEPTORMEN1KMT2ARAB9ANPC1
SCHEMBL924746 0.83 DEPTOR (0.42) DEPTORALDH1A1HTTNOX1MEN1
SCHEMBL924360 0.83 DEPTOR (0.42) DEPTORALDH1A1HTTNOX1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6214813-B1 AZOPYRAZOLES KINETEK PHARMACEUTICALS, INC. (CA) 2001-04-10 — — US claimed
US-20230321043-A1 COMPOUNDS HAVING PSEUDOMONAS ANTI-BIOFILM PROPERTIES UNIV COPENHAGEN (DK) 2023-10-12 — — US disclosed
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS DERMIRA (CANADA), INC. (US) 2014-04-17 — — US disclosed
US-8445694-B2 Hydrazonopyrazole derivatives and their use as therapeutics DERMIRA (CANADA), INC. (US) 2013-05-21 — — US disclosed
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Valocor Therapeutics, Inc. (CA) 2011-09-29 — — US disclosed
US-7875728-B2 tert-butyl-[5-methyl-4-(phenylhydrazono)-4H-pyrazol-3-yl]amine; 4-(3-fluorophenylhydrazono)-5-methyl-2H-pyrazol-3-ylamine; demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death Valocor Therapeutics, Inc. (CA) 2011-01-25 — — US disclosed
US-7105503-B2 Pyrazole compounds QLT INC. (CA) 2006-09-12 — — US disclosed
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof DERMIRA (CANADA), INC. 2005-12-08 — — US disclosed
EP-1450791-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS Kinetek Pharmaceuticals, Inc. (CA) 2004-09-01 — — EP disclosed
WO-2003045379-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS KINETEK PHARMACEUTICALS, INC. (CA) 2003-06-05 — — WO disclosed
US-20030060453-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2003-03-27 — — US disclosed
EP-1276723-A2 PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY Kinetek Pharmaceuticals, Inc. (CA) 2003-01-22 — — EP disclosed
US-6436915-B1 ANTIPROLIFERATIVE AND ANTITUMOR AGENTS AND ANGIOGENESIS INHIBITORS KINETEK PHARMACEUTICALS, INC. (CA) 2002-08-20 — — US disclosed
US-20020042501-A1 Pyrazole compounds DERMIRA (CANADA), INC. 2002-04-11 — — US disclosed
WO-2001077080-A2 PYRAZOLE COMPOUNDS HAVING ANTI PROLIFERATIVE ACTIVITY KINETEK PHARMACEUTICALS, INC. (CA) 2001-10-18 — — WO disclosed
US-6214813-B1 AZOPYRAZOLES KINETEK PHARMACEUTICALS, INC. (CA) 2001-04-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321043-A1 COMPOUNDS HAVING PSEUDOMONAS ANTI-BIOFILM PROPERTIES GMPS, PDE11A, CGAS DEPTOR 1931/4885ALDH1A1 3702/4885HTT 1442/4885
US-20110237783-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 DEPTOR 1170/4885ALDH1A1 1614/4885HTT 1145/4885
US-20140107125-A1 HYDRAZONOPYRAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTICS CDK4, CCNI, BCL2 DEPTOR 1170/4885ALDH1A1 1614/4885HTT 1145/4885
US-20050272709-A1 Immugenic compositions and diagnostic and therapeutic uses thereof MKI67, CDK4, CCNC DEPTOR 200/4885ALDH1A1 3393/4885HTT 1642/4885
US-20030060453-A1 Pyrazole compounds CCNC, MKI67, CDC25C DEPTOR 899/4885ALDH1A1 2487/4885HTT 2491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.